MM
Mahave, M.
2 yayın · 38 atıf · 2024–2024
Yayın
2
Atıf
38
Yıllar
1
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Meeting Abstract | 38 |
|
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
|
2024 | Meeting Abstract | 0 |